NEW YORK (GenomeWeb) – Biofortuna today announced it has raised £1.6 million ($2.1 million) to support taking its genotyping assays into clinical trials and commercialization.

Investors in the new funding round included current investor venture capital firm Foresight and members of Biofortuna's senior management team. The company said that the funds will be used to take its ReadyPlex rapid blood group genotyping assays further toward commercialization, and allow Biofortuna to invest in additional resources in its contract manufacturing infrastructure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.